Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list

(Reuters) – Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk’s weight loss and diabetes drugs Wegovy and Ozempic from its shortage list, a move that will sharply curtail the compounders’ ability to sell cheaper versions of the drugs.

(Reporting By Brendan Pierson in New York; Editing by Leslie Adler)